The estimated Net Worth of Aaron Schuchart is at least $87 Tisíc dollars as of 27 September 2018. Aaron Schuchart owns over 6,000 units of Aeglea BioTherapeutics Inc stock worth over $30,025 and over the last 7 years Aaron sold AGLE stock worth over $57,000.
Aaron has made over 2 trades of the Aeglea BioTherapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Aaron sold 6,000 units of AGLE stock worth $57,000 on 27 September 2018.
The largest trade Aaron's ever made was exercising 8,500 units of Aeglea BioTherapeutics Inc stock on 17 August 2018 worth over $29,750. On average, Aaron trades about 2,417 units every 7 days since 2017. As of 27 September 2018 Aaron still owns at least 2,500 units of Aeglea BioTherapeutics Inc stock.
You can see the complete history of Aaron Schuchart stock trades at the bottom of the page.
Aaron's mailing address filed with the SEC is C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN, TX, 78746.
Over the last 9 years, insiders at Aeglea BioTherapeutics Inc have traded over $1,425,674 worth of Aeglea BioTherapeutics Inc stock and bought 1,931,829 units worth $12,152,489 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bioventures Ltd Novartis Ag... a Advisors Llc Orbi Med Capit.... On average, Aeglea BioTherapeutics Inc executives and independent directors trade stock every 70 days with the average trade being worth of $864,564. The most recent stock trade was executed by Marcio Souza on 25 August 2022, trading 90,000 units of AGLE stock currently worth $50,400.
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
Aeglea BioTherapeutics Inc executives and other stock owners filed with the SEC include: